Richard T. Maziarz
AdvisorDr. Richard T. Maziarz, M.D., serves as Member of Scientific Advisory Board at Bone Therapeutics SA since October 2021. He served as Member of Scientific Advisory Board at CytoDyn Inc. since September 2020. Dr. Maziarz serves as Scientific and Clinical Advisor of BTHC VI, Inc. Dr. Maziarz serves as Principal Investigator of and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU) Health Sciences University. Dr. Maziarz is a Professor and Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU). Dr. Maziarz served as Member of Advisory Board at Gamida Cell Ltd. until December 2019. He specializes in bone marrow transplantation and hematologic malignancies. His research interests cover function of the cellular immune system after bone marrow transplantation, molecular immunology and tumor immunology. Dr. Maziarz’s clinical interests include leukemia, lymphoma, graft vs. host disease and immunotherapy. Dr. Maziarz holds Degree from Harvard Medical School, Boston, in 1979 and Fellowships from Harvard Medical School, Brigham and Women. He resides at University Hospitals of Cleveland, Cleveland. He is Member of Advisory Board at Artiva Biotherapeutics, Inc.
Positions
- Company NameArtiva Biotherapeutics, Inc.Stock CodeARTVPositionAdvisorColleagues
- FAFred AslanCEO, Principal Financial & Accounting Officer and Director
- BFBrian F. DanielsIndependent Chairman of the Board
- GDGines Diego MirallesPresident and Head of Research & Development
- JKJennifer Kinsbruner BushChief Operating Officer
- CPChristopher P. HoranChief Technical Operations Officer
- PFPeter FlynnCo-Founder & Strategic Advisor
- LSLaura StoppelIndependent Director
